Blueprint Medicines Corp (NASDAQ:BPMC) shares, rose in value, with the stock price up by 3.14% to the previous day’s close as strong demand from buyers drove the stock to $84.69.
Actively observing the price movement in the last trading, the stock closed the session at $82.11, falling within a range of $81.37 and $84.97. The value of beta (5-year monthly) was 0.746. Referring to stock’s 52-week performance, its high was $121.90, and the low was $73.04. On the whole, BPMC has fluctuated by -6.40% over the past month.
With the market capitalization of Blueprint Medicines Corp currently standing at about $5.41 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-12.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 724.08M, with a low estimate of 145.2M and a high estimate of 236M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 158.09M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BPMC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of BPMC currently trading nearly -1.11% and -6.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.15, while the 7-day volatility ratio is showing 4.55% which for the 30-day chart, stands at 5.59%. Furthermore, Blueprint Medicines Corp (BPMC)’s beta value is 0.85, and its average true range (ATR) is 4.51.
A comparison of Blueprint Medicines Corp (BPMC) with its peers suggests the former has fared considerably weaker in the market. BPMC showed an intraday change of 3.14% in last session, and over the past year, it shrunk by -1.63%%.
Data on historical trading for Blueprint Medicines Corp (NASDAQ:BPMC) indicates that the trading volumes over the past 10 days have averaged 1.31 and over the past 3 months, they’ve averaged 1.08 million. According to company’s latest data on outstanding shares, there are 63.71 million shares outstanding.
Nearly 1.97% of Blueprint Medicines Corp’s shares belong to company insiders and institutional investors own 106.00% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.4 million shares as on 2025-03-31, resulting in a short ratio of 5.17. According to the data, the short interest in Blueprint Medicines Corp (BPMC) stood at 951.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 4.71 million. The stock has fallen by -2.90% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BPMC stock heading into the next quarter.
